1. GPCR/G Protein
  2. GNRH Receptor

Elagolix (Synonyms: NBI-56418)

Cat. No.: HY-14789
Handling Instructions

Elagolix is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM).

For research use only. We do not sell to patients.
Elagolix Chemical Structure

Elagolix Chemical Structure

CAS No. : 834153-87-6

Size Price Stock Quantity
10 mM * 1 mL in DMSO $486 In-stock
5 mg $350 In-stock
10 mg $500 In-stock
50 mg $1500 In-stock
100 mg $2100 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • References

Description

Elagolix is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM). Target: GnRH in vitro: Elagolix is a short-acting, nonpeptide, GnRH antagonist, administered orally, that unlike injectable depot GnRH agonists and antagonists, produces a dose-dependent suppression of ovarian estrogen production, that is, from partial suppression at lower doses to full suppression at higher doses. Elagolix is regarded as the frontrunner of a new class of GnRH inhibitors that have been denoted as second-generation, due to their non-peptide nature and oral bioavailability.

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01441635 AbbVie (prior sponsor, Abbott)|AbbVie Heavy Uterine Bleeding|Uterine Fibroids September 2011 Phase 2
NCT01620528 AbbVie (prior sponsor, Abbott)|AbbVie Endometriosis May 2012 Phase 3
NCT02925494 AbbVie Uterine Fibroids|Heavy Menstrual Bleeding September 14, 2016 Phase 3
NCT01931670 AbbVie Endometriosis September 2013 Phase 3
NCT02654054 AbbVie Uterine Fibroids|Heavy Menstrual Bleeding November 7, 2015 Phase 3
NCT03213457 AbbVie Endometriosis July 7, 2017 Phase 3
NCT02143713 AbbVie Endometriosis May 27, 2014 Phase 3
NCT02691494 AbbVie Uterine Fibroids|Heavy Menstrual Bleeding January 4, 2016 Phase 3
NCT01760954 AbbVie Endometriosis December 2012 Phase 3
NCT01403038 AbbVie (prior sponsor, Abbott)|Neurocrine Biosciences|AbbVie Folliculogenesis June 2011 Phase 1
NCT01817530 AbbVie Heavy Uterine Bleeding|Uterine Fibroids January 2013 Phase 2
NCT00973973 AbbVie (prior sponsor, Abbott)|AbbVie Endometriosis|Pain August 2009 Phase 2
NCT00437658 AbbVie (prior sponsor, Abbott)|AbbVie Endometriosis November 2006 Phase 2
NCT00619866 AbbVie (prior sponsor, Abbott)|AbbVie Endometriosis, Pain December 2007 Phase 2
NCT00797225 AbbVie (prior sponsor, Abbott)|AbbVie Endometriosis November 2008 Phase 2
NCT00109512 Abbott Endometriosis April 2005 Phase 2
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 1.5833 mL 7.9165 mL 15.8331 mL
5 mM 0.3167 mL 1.5833 mL 3.1666 mL
10 mM 0.1583 mL 0.7917 mL 1.5833 mL
References
Molecular Weight

631.59

Formula

C₃₂H₃₀F₅N₃O₅

CAS No.

834153-87-6

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Elagolix
Cat. No.:
HY-14789
Quantity: